2033 Westport Center Dr
Tel: (314) 400-6627
109 articles with Horizon Discovery
10/3/2019Companies from across the globe share information on their business and pipelines.
Horizon Discovery Signs License Agreement With Glenmark Pharmaceuticals for GS Knockout CHO Cell Line for Manufacture of Biotherapeutics
Glenmark signs full commercial-use license for Horizon’s gene-edited CHO cells
Horizon Discovery Group plc announces its results for the six months ended 30 June 2019.
Batavia Biosciences to deploy Horizon Discovery’s CHO cell technology to develop anti-Zika biotherapeutic with Vanderbilt University Medical Center and IDBiologics
Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines.
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, provides a trading update for the six month period ended 30 June 2019.
7/11/2019Companies from across Europe, Asia and around the globe share pipeline and business updates.
Horizon Discovery’s SMARTvector shRNA Technology Deployed in Celyad’s Successful IND Filing for Next-Generation CAR-T Cell Therapy, CYAD-02
Horizon Discovery Group plc, announced that Celyad, a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, received FDA Acceptance of Investigational New Drug application for the autologous NKG2D based CAR-T cell therapy CYAD-02 that deploys Horizon’s optimized SMARTvector™ shRNA technology.
BioSpace takes a quick look at some of the news coming from biotech and pharma companies from across Europe and Asia.
Full year results for the year ended 31 December 2018 will be announced on Monday 29 April 2019.
It’s no secret that the global biopharma and life sciences industry is large. Sometimes the immense size of the industry can lead fascinating news tidbits to fall through the cracks, particularly those from smaller companies scattered across the globe. This week BioSpace will launch a new roundup...
Horizon Discovery and Rutgers University Form Exclusive Partnership to Develop Next Generation Novel Gene Editing Technology
Horizon will work with Rutgers University to develop and commercialise base editing platform for therapeutic and research applications
Horizon Discovery partners with Biocartis to provide reference standards for recently launched Idylla™ microsatellite instability assay
First commercially available reference standard for microsatellite instability (MSI) testing
Horizon Discovery Group plc, announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.
Horizon Discovery Edit-R crRNA Libraries Adopted by AstraZeneca as Part of its Functional Genomics Discovery Platform
AstraZeneca joins Horizon’s Genomics Discovery Initiative
Horizon Discovery announces collaboration with major pharmaceutical company on single cell RNAseq-linked CRISPR screening
Co-development and implementation of a new CRISPR-based screening technology platform to address critical gaps in target ID and validation
5/13/2018Biotech companies tapped a number of new upper management and c-suite executives last week. BioSpace put together a roundup of some of the latest appointments in the industry, which includes a number of new chief executive officers hired to helm companies.
Horizon’s Glutamine Synthetase-Knockout CHO K1 cell line has been used as part of a successful Investigational New Drug filing with the FDA
Under the terms of the agreement, Horizon has licensed to the Partner a novel cell line engineering technology as well as non-exclusive rights to Horizon's proprietary Helitron transposon gene editing technology for an undisclosed financial consideration.
Horizon has licensed to the Partner a novel cell line engineering technology as well as non-exclusive rights to Horizon's proprietary Helitron transposon gene editing technology for an undisclosed financial consideration.
Horizon Discovery today announces an unaudited pre-close period update for the year ended 31 December 2017.